Old King Coal - Molecular mechanisms underlying an ancient treatment for atopic eczema

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 551-553

  Irwin McLean, W H ^a   Irvine, Alan D ^b,c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

COAL TAR; FILAGGRIN;

ATOPIC DERMATITIS; CELLULAR IMMUNITY; DRUG EFFICACY; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; KERATINOCYTE; NETHERLANDS; PRIORITY JOURNAL; REVIEW; TH2 CELL; TRADITIONAL MEDICINE;

COAL TAR; DERMATITIS, ATOPIC; HUMANS; RECEPTORS, ARYL HYDROCARBON;

EID: 84873326575     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67438     Document Type: Review

References (15)

1. Irvine AD, McLean WHI, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315-1327.
2. Novak N, Leung DY. Advances in atopic dermatitis. Curr Opin Immunol. 2011;23(6):778-783.
3. Smith FJD, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006;38(3):337-342.
4. Sandilands A, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39(5):650-654.
5. Palmer CNA, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446.
6. Fallon PG, et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet. 2009;41(5):602-608.
7. Dioscorides P. Book 1: Aromatics. In: Osbaldeston TA, Wood RPA, eds. Dioscorides: De Materia Medica (A new indexed version in modern English). Johannesburg, South Africa: Ibidis Press; 2000:99-100.
8. Thami GP, Sarkar R. Coal tar: past, present and future. Clin Exp Dermatol. 2002;27(2):99-103.
9. Slutsky JB, Clark RA, Remedios AA, Klein PA. An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol. 2010;9(10):1258-1264.
10. Mainstone J. The Pitch Drop Experiment. The University of Queensland Web site. http://smp. uq.edu. au/content/pitch-drop-experiment. Accessed December 10, 2012.
11. Choudhary G, Citra MJ, McDonald AR, Quiñone-Rivera A. Toxicological Profile for Wood Creosote, Coal Tar Creosote, Coal Tar, Coal Tar Pitch, and Coal Tar Pitch Volatiles. Atlanta, Georgia, USA; US Department of Health and Human Services; 2002.
12. Van Den Bogaard EH, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013;123(2):917-927.
13. Du L, Hoffman SM, Keeney DS. Epidermal CYP2 family cytochromes P450. Toxicol Appl Pharmacol. 2004;195(3):278-287.
14. Smith G, et al. Regulation of cutaneous drugmetabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol. 2006;155(2):275-281.
15. Roelofzen JH, et al. DNA adducts in skin biopsies and 1-hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar. Toxicol Lett. 2012;213(1):39-44.